The treatment of brain metastases from malignant melanoma
JG Douglas, K Margolin - Seminars in oncology, 2002 - Elsevier
Metastasis to the CNS develops in nearly half of patients with advanced melanoma; in 15%
to 20% of these patients, the CNS is the first site of relapse. While systemic therapy for
metastatic melanoma produces objective responses in 15% to 50% of patients, the available
drugs do not penetrate well into the CNS, and these patients rarely benefit from systemic
therapy. Although brain metastasis may be treated with surgery and/or stereotactic
radiosurgery (SRS) when disease is limited to approximately one to three lesions, treatment …
to 20% of these patients, the CNS is the first site of relapse. While systemic therapy for
metastatic melanoma produces objective responses in 15% to 50% of patients, the available
drugs do not penetrate well into the CNS, and these patients rarely benefit from systemic
therapy. Although brain metastasis may be treated with surgery and/or stereotactic
radiosurgery (SRS) when disease is limited to approximately one to three lesions, treatment …
